Interferon-α-2b and ribavirin for retreatment of chronic hepatitis C

Hepato-Gastroenterology

Volumn 49, Issue 45, 2002, Pages 758-763

  Dettmer, Robert M ^a   Reinus, John F ^a   Clain, David J ^a   Aytaman, Ayse ^a   Levendoglu, Hulya ^a   Bloom, Alan A ^a   Isaacson, Mary P ^a   Spinnell, Mitchel ^a   Meyer, Douglas ^a   Sarabanchong, Viyada ^a   Zhang, Yatian ^a   Garcia Carrasquillo, Reuben J ^a   Markowitz, David D ^a   Magun, Arthur M ^a   Worman, Howard J ^a  

^a Columbia University ^*  (United States)

Author keywords

Cirrhosis; Hepatitis C; Interferon alpha; Liver; Ribavirin; Viral hepatitis

Indexed keywords

AMINOTRANSFERASE; PLACEBO; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA; ALPHA2B INTERFERON;

ADULT; AGED; ANEMIA; ANGINA PECTORIS; ARTICLE; ASCITES; CHRONIC HEPATITIS; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOSIS; TREATMENT OUTCOME; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; GENETICS; HEPATITIS C; HEPATITIS C VIRUS; MIDDLE AGED; RETREATMENT;

ADULT; AGED; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; INTERFERON ALFA-2B; MALE; MIDDLE AGE; RETREATMENT; RIBAVIRIN; RNA, VIRAL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; HUMANS; MIDDLE AGED;

EID: 0036016764     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Treatment of chronic non-A, non-B hepatitis with recombinant human α-interferon. A preliminary report
2. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial
3. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
4. The treatment of chronic viral hepatitis
5. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis
6. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
7. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
8. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C
9. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial
10. Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy
11. Escalating interferon-α-2b dose for patients with chronic hepatitis C
12. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C
13. Ribavirin and interferon-α combination therapy vs interferon-α alone in the retreatment of chronic hepatitis C: A randomized clinical trial
14. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: Results of a randomized, controlled trial
15. Interferon-α-2b and ribavirin in combination for chronic hepatitis C patients not responding to interferon-α alone: An Italian multicenter, randomized, controlled, clinical study
16. Treatment with interferon-α-2a alone or interferon-α-2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-α-2a
17. Pilot study of triple antiviral therapy for chronic hepatitis C in interferon-α non-responders
18. Interferon-α plus ribavirin in chronic hepatitis C resistant to previous interferon-α course: Results of a randomized multicenter trial
19. Retreatment of non-responder or relapser chronic hepatitis C patients with interferon plus ribavirin vs interferon alone
20. A randomized trial of ribavirin and interferon-α vs. interferon-α alone in patients with chronic hepatitis C who were non-responders to a previous treatment
21. Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: A randomized trial
22. Interferon-α-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon-α therapy: A randomized trial
23. Long-term re-treatment with interferon and ribavirin combination therapy in patients with chronic hepatitis C who are non-responders to interferon alone: A preliminary study
24. Relationship between biochemical, virological and histological response during interferon treatment of chronic hepatitis C
25. Viral and host factors in the prediction of relapse to interferon-α therapy in chronic hepatitis C after long term followup
26. Influence of pre-treatment on outcome of interferon-α treatment on patients with chronic hepatitis C
27. Interferon retreatment in chronic hepatitis C: Which patients to choose and what schedule to use
28. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C: Meta-analysis of individual patient data from European centers
29. Randomised, double-blind, placebo-controlled trial of interferon-α-2b with and without ribavirin for chronic hepatitis C
30. Randomised trial of interferon-α-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon-α-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
31. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
32. The crystal structure of hepatitis C virus NS3 proeinase reveals a trypsin-like fold and a structural zinc binding site
33. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide
34. Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain
35. Structure of the hepatitis C virus RNA helicase domain
36. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: The crystal structure provides insights into the mode of unwinding
37. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus a fully encircled active site